Sarah Neidler

Sarah Neidler

Auto-generated profile, based on publicly available information

Sarah Neidler

Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
NMNathiya Muthalagu
Nathiya Muthalagu
TMTiziana Monteverde
Tiziana Monteverde
XRXimena Raffo-Iraolagoitia
Ximena Raffo-Iraolagoitia
RWRobert Wiesheu
Robert Wiesheu
DWDeclan Whyte
Declan Whyte
Daniel J. MurphyDaniel J. Murphy
Daniel J. Murphy
MYC is implicated in the development and progression of pancreatic cancer, yet the precise level of MYC deregulation required to contribute to tumor development has been difficult to define. We used modestly elevated expression of human MYC, driven from the Rosa26 locus, to investigate the pancreatic phenotypes arising in mice from an approximation of MYC trisomy. We show that this level of MYC alone suffices to drive pancreatic neuroendocrine tumors, and to accelerate progression of KRAS-initiated precursor lesions to metastatic pancreatic ductal adenocarcinoma (PDAC). Our phenotype exposed suppression of the type I interferon (IFN) pathway by the combined actions of MYC and KRAS, and we present evidence of repressive MYC–MIZ1 complexes binding directly to the promoters of the genes encodiing the type I IFN regulators IRF5, IRF7, STAT1, and STAT2. Derepression of IFN regulator genes allows pancreatic tumor infiltration by B and natural killer (NK) cells, resulting in increased survival. Significance: We define herein a novel mechanism of evasion of NK cell–mediated immunity through the combined actions of endogenously expressed mutant KRAS and modestly deregulated expression of MYC, via suppression of the type I IFN pathway. Restoration of IFN signaling may improve outcomes for patients with PDAC. This article is highlighted in the In This Issue feature, p. 747

20 June 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
BKBjörn Kruspig
Björn Kruspig
TMTiziana Monteverde
Tiziana Monteverde
SNSarah Neidler
Sarah Neidler
AHAndreas Hock
Andreas Hock
EKEmma Kerr
Emma Kerr
Daniel J. MurphyDaniel J. Murphy
Daniel J. Murphy
KRAS is the most frequently mutated driver oncogene in human adenocarcinoma of the lung. There are presently no clinically proven strategies for treatment of KRAS-driven lung cancer. Activating mutations in KRAS are thought to confer independence from upstream signaling; however, recent data suggest that this independence may not be absolute. We show that initiation and progression of KRAS-driven lung tumors require input from ERBB family receptor tyrosine kinases (RTKs): Multiple ERBB RTKs are expressed and active from the earliest stages of KRAS-driven lung tumor development, and treatment with a multi-ERBB inhibitor suppresses formation of KRASG12D-driven lung tumors. We present evidence that ERBB activity amplifies signaling through the core RAS pathway, supporting proliferation of KRAS-mutant tumor cells in culture and progression to invasive disease in vivo. Brief pharmacological inhibition of the ERBB network enhances the therapeutic benefit of MEK (mitogen-activated protein kinase kinase) inhibition in an autochthonous tumor setting. Our data suggest that lung cancer patients with KRAS-driven disease may benefit from inclusion of multi-ERBB inhibitors in rationally designed treatment strategies.

3 April 2023
Verified
Other
Open access
NMNathiya Muthalagu
Nathiya Muthalagu
TMTiziana Monteverde
Tiziana Monteverde
XRXimena Raffo-Iraolagoitia
Ximena Raffo-Iraolagoitia
RWRobert Wiesheu
Robert Wiesheu
DWDeclan Whyte
Declan Whyte
Daniel J. MurphyDaniel J. Murphy
Daniel J. Murphy
6 supplementary Figures with legends under each; 3 Supplementary Tables; Supplementary Methods and References

3 April 2023
Verified
Other
Open access
NMNathiya Muthalagu
Nathiya Muthalagu
TMTiziana Monteverde
Tiziana Monteverde
XRXimena Raffo-Iraolagoitia
Ximena Raffo-Iraolagoitia
RWRobert Wiesheu
Robert Wiesheu
DWDeclan Whyte
Declan Whyte
Daniel J. MurphyDaniel J. Murphy
Daniel J. Murphy
6 supplementary Figures with legends under each; 3 Supplementary Tables; Supplementary Methods and References

3 April 2023
Verified
Other
Open access
NMNathiya Muthalagu
Nathiya Muthalagu
TMTiziana Monteverde
Tiziana Monteverde
XRXimena Raffo-Iraolagoitia
Ximena Raffo-Iraolagoitia
RWRobert Wiesheu
Robert Wiesheu
DWDeclan Whyte
Declan Whyte
Daniel J. MurphyDaniel J. Murphy
Daniel J. Murphy
MYC is implicated in the development and progression of pancreatic cancer, yet the precise level of MYC deregulation required to contribute to tumor development has been difficult to define. We used modestly elevated expression of human MYC, driven from the Rosa26 locus, to investigate the pancreatic phenotypes arising in mice from an approximation of MYC trisomy. We show that this level of MYC alone suffices to drive pancreatic neuroendocrine tumors, and to accelerate progression of KRAS-initiated precursor lesions to metastatic pancreatic ductal adenocarcinoma (PDAC). Our phenotype exposed suppression of the type I interferon (IFN) pathway by the combined actions of MYC and KRAS, and we present evidence of repressive MYC–MIZ1 complexes binding directly to the promoters of the genes encodiing the type I IFN regulators IRF5, IRF7, STAT1, and STAT2. Derepression of IFN regulator genes allows pancreatic tumor infiltration by B and natural killer (NK) cells, resulting in increased survival.Significance:We define herein a novel mechanism of evasion of NK cell–mediated immunity through the combined actions of endogenously expressed mutant KRAS and modestly deregulated expression of MYC, via suppression of the type I IFN pathway. Restoration of IFN signaling may improve outcomes for patients with PDAC.This article is highlighted in the In This Issue feature, p. 747

3 April 2023
Verified
Other
Open access
NMNathiya Muthalagu
Nathiya Muthalagu
TMTiziana Monteverde
Tiziana Monteverde
XRXimena Raffo-Iraolagoitia
Ximena Raffo-Iraolagoitia
RWRobert Wiesheu
Robert Wiesheu
DWDeclan Whyte
Declan Whyte
Daniel J. MurphyDaniel J. Murphy
Daniel J. Murphy
Spreadsheet of genes co-regulated by MYC & Miz1 in KMC PDAC cells